Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued in December 2016

CEL-SCI Corporation
Posted on: 29 Aug 17

CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD and Series EE warrants to July 1, 2018 (close of business). The Series DD and Series EE warrants were issued on December 8, 2016. Following the Company’s reverse split in June 2017, twenty-five (25) Series DD and Series EE warrants will be required to purchase one share at an exercise price of $4.50. All other terms of the warrants have remained the same.

About CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

View source version on

Business Wire

Last updated on: 23/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.